Strata Skin SciencesSSKN
SSKN
About: Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
Employees: 106
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
13% more funds holding
Funds holding: 16 [Q4 2024] → 18 (+2) [Q1 2025]
0.57% more ownership
Funds ownership: 28.95% [Q4 2024] → 29.52% (+0.57%) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
7% less capital invested
Capital invested by funds: $3.51M [Q4 2024] → $3.25M (-$258K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for SSKN.
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
STRATA Skin Sciences, Inc. (SSKN) Q1 2025 Earnings Call Transcript
STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Jules Abraham - CORE IR Dolev Rafaeli - Chief Executive Officer John Gillings - VP of Finance Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Jeremy Pearlman - Maxim Group Operator Good afternoon, and welcome to the STRATA Skin Sciences First Quarter 2025 Financial Results Conference Call. All participants will be in a listen-only mode.
Neutral
GlobeNewsWire
1 month ago
STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update.
Neutral
GlobeNewsWire
1 month ago
STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference
HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will participate in the D. Boral Capital Inaugural Global Conference. The conference is being held on May 14, 2025, at The Plaza Hotel, 768 Fifth Avenue, New York, NY 10019.
Neutral
GlobeNewsWire
1 month ago
STRATA Skin Sciences to Report First Quarter 2025 Financial Results on May 14, 2025 and Provide Corporate Update
HORSHAM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2025 financial results on Wednesday, May 14, 2025 after the market close.
Neutral
Seeking Alpha
2 months ago
STRATA Skin Sciences, Inc. (SSKN) Q4 2024 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:00 PM ET STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q4 2024 Earnings Conference Call March 27, 2025, 16:30 PM ET Company Participants Dolev Rafaeli - CEO John Gillings - VP of Finance Louie Toma - CORE IR Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Jeremy Pearlman - Maxim Group Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the STRATA Skin Sciences, Inc. Fourth Quarter and Year End 2024 Financial Results and Corporate Update Conference Call.
Neutral
GlobeNewsWire
2 months ago
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Corporate Update
HORSHAM, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter and year ended December 31, 2024, and provides a corporate update.
Neutral
GlobeNewsWire
2 months ago
STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update
HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close.
Neutral
GlobeNewsWire
2 months ago
STRATA Skin Sciences Highlights New Clinical Study from Japan Demonstrating Superiority of Narrow Band Excimer Laser Over Non Narrow Band UVB-Source Like Excimer Light
HORSHAM, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the results of a newly published study in Japan that further validates the technological advantages of high repetition rate, high dose, coherent collimated narrow band Excimer Laser technology over other sources of UVB light that are less accurate, lack the repetition rate and/or fluence capabilities of an Excimer Light for treating Vitiligo, Psoriasis, Alopecia Areata and Atopic Dermatitis. The study, titled “Excimer Laser Penetrates Deeper into Hair Follicles and Activates More Melanocyte Lineage Cells than Excimer Light,” authored by distinguished researchers from the Nippon Medical School and published in the peer reviewed Journal of Nippon Medical School, demonstrates that despite the two devices producing same 308-nm wavelength, the distinct technological characteristics between two devices can have significant impact on the clinical outcomes. Notably, the excimer laser exhibits laser properties (monochromatic coherent light) and unique device specifications (a high frequency of 400 Hz and a remarkably high irradiance that leads to cellular differences such as deeper penetration, greater activation of melanocyte lineage cells (melanocyte stem cells (McSCs) and melanoblasts) resulting in superior clinical outcomes in terms of greater pigmentation and fewer epidermal side effects relative to excimer light. This study provides further scientific evidence that the modality generating UVB light has significant impact on the clinical outcomes of a device.
Positive
Zacks Investment Research
5 months ago
Why Fast-paced Mover Strata Skin Sciences (SSKN) Is a Great Choice for Value Investors
Strata Skin Sciences (SSKN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Neutral
GlobeNewsWire
6 months ago
STRATA Skin Sciences to Participate in the Benchmark Company 13th Annual Discovery Investor Conference
HORSHAM, Pa., Dec. 05, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that President and Chief Executive Officer Dr. Dolev Rafaeli will participate in the Benchmark Company 13th Annual Discovery Investor Conference that is being held on Wednesday, December 11, 2024, at the New York Athletic Club in New York City.
Charts implemented using Lightweight Charts™